Srinivasan G, et al. - In this study, a hypothesis has been made that BAP1-mutant malignant pleural mesotheliomas (MPM) would require PARP1 for survival, similar to the BRCA1/2 mutant breast and ovarian cancers. Researchers here used the clinical PARP1 inhibitors niraparib and olaparib to assess whether they could induce synthetic lethality in MPM. Findings proved that the PARP1 inhibitors could be efficacious in the treatment of MPM, for which little effective therapy exists.